Spectral Medical Inc. (EDT.TO)
| Previous Close | 0.4900 |
| Open | 0.5000 |
| Bid | 0.4950 x 0 |
| Ask | 0.5100 x 0 |
| Day's Range | 0.5000 - 0.5300 |
| 52 Week Range | 0.2250 - 0.6700 |
| Volume | |
| Avg. Volume | 63,744 |
| Market Cap | 139.697M |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 19, 2011 |
| 1y Target Est | N/A |
- GlobeNewswire
Spectral Medical Announces First Quarter Results and Provides Corporate Update
Tigris Trial Enrollment Reaches 106 Patients Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update. Spectral has continued its significant progress throughout the fi
- GlobeNewswire
Spectral Medical Inc. Announces C$8.5 Million Bought Deal Convertible Note Financing
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA. TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX:EDT) (the "Company" or "Spectral"), is pleased to announce that it has entered into an agreement with Paradigm Capital Inc. (the "Underwriter"), in connection with a bought deal priva
- GlobeNewswire
Spectral Medical Provides April Tigris Trial Update
• 105 patients enrolled • April represents a record breaking month for patient enrollment TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and sep
